{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"34","value":"20"},{"groupId":"OG001","lowerLimit":"13","upperLimit":"37","value":"23"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"17","value":"6"},{"groupId":"OG001","lowerLimit":"3","upperLimit":"21","value":"10"}]}],"title":"sCR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25","upperLimit":"54","value":"39"},{"groupId":"OG001","lowerLimit":"25","upperLimit":"53","value":"38"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"comment":"95% CI lower limit is \\<1.","groupId":"OG000","lowerLimit":"NA","upperLimit":"11","value":"2"},{"comment":"95% CI lower limit is \\<1.","groupId":"OG001","lowerLimit":"NA","upperLimit":"10","value":"2"}]}],"title":"nCR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52","upperLimit":"80","value":"67"},{"groupId":"OG001","lowerLimit":"51","upperLimit":"78","value":"65"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"17","value":"6"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"16","value":"6"}]}],"title":"MR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"}],"units":"Participants"}],"description":"Response was assessed by the investigator using International Myeloma Working Group (IMWG) Criteria. CR=Negative immunofixation on the serum and urine + Disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow. sCR= CR + Normal free light chain (FLC) ratio and Absence of clonal cells in bone marrow. PR=≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \\< 200 mg per 24 hours. VGPR= Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hours. nCR=Positive immunofixation analysis of serum or urine as the only evidence of disease. Disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow. MR=25% to 49% reduction in serum paraprotein and 50% to 89% reduction in urine light chain excretion for 6 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone"},{"description":"In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once, on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once, on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Includes 3 participants who received 2.23 mg/m\\^2 in Phase 1.","id":"OG001","title":"Phase 2: Ixazomib 4.0 mg/2.23 + Lenalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"The response-evaluable population was defined as all patients who received at least one dose of ixazomib, had measurable disease at baseline, and at least one post-baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"Cycles 3, 6, 9 and 12 (Up to 787 days)","title":"Phase 2: Percentage of Participants With Complete Response (CR), Stringent Complete Response (sCR), Very Good Partial Response (VGPR), Near Complete Response (nCR), Partial Response (PR) and Minimal Response (MR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}